Aligos Therapeutics Cuts Losses 82% While Advancing Hepatitis B Pipeline

Aligos Therapeutics delivered a significantly improved financial performance for 2025 while simultaneously progressing its pipeline of infectious disease treatments, marking a potential inflection point for the clinical-stage biopharmaceutical company. The company reported a net loss of $24.2 million for the full year 2025—a dramatic 82% improvement compared to the $131.2 million loss recorded in 2024—as it simultaneously achieved multiple clinical milestones in its battle against chronic hepatitis B and metabolic disease.

The financial turnaround reflects Aligos' focused approach to capital deployment and operational efficiency. With cash and investments totaling $77.8 million as of the end of 2025, the company projects sufficient liquidity to fund operations into Q3 2026, providing a meaningful window for clinical data readouts and potential catalysts that could reshape investor sentiment toward the company.

Clinical Progress: Moving Closer to Market Potential

The company's most significant clinical achievement centers on pevifoscorvir sodium, a nucleotide polymerase inhibitor being evaluated for chronic hepatitis B. Aligos announced the completion of HBeAg-negative participant enrollment in its Phase 2 B-SUPREME study, with interim analyses now expected throughout 2026. This milestone represents critical progress in a large patient population that has historically proven challenging to treat effectively.

Beyond the flagship hepatitis B program, Aligos has accelerated its pipeline expansion:

• ALG-170675: An innovative dual-mechanism antisense oligonucleotide has advanced into IND-enabling studies through a partnership with Xiamen Amoytop Biotech, broadening the company's geographic reach and development capacity
• ALG-055009: Demonstrated synergistic weight loss results when combined with incretin receptor agonists, positioning the compound within the rapidly expanding metabolic disease landscape that has captured significant investor attention following the blockbuster success of GLP-1 receptor agonists

The hepatitis B opportunity remains substantial. Approximately 257 million people worldwide carry chronic hepatitis B infection, yet treatment options remain limited, particularly for HBeAg-negative patients who often experience more aggressive disease progression. A successful Phase 2 readout could open significant commercial opportunities and attract potential partnership or acquisition interest.

Market Context: Positioning in Competitive Therapeutic Landscape

Aligos operates in a dynamic competitive environment shaped by several macroeconomic and therapeutic trends. The hepatitis B antiviral market has seen renewed interest as newer, more potent therapies demonstrate improved efficacy and safety profiles compared to legacy treatments. Companies including Gilead Sciences ($GILD) and Vir Biotechnology ($VIR) have also prioritized hepatitis B programs, underscoring the market's attractiveness and potential for differentiated therapeutics.

The company's expansion into metabolic disease through its ALG-055009 program reflects astute strategic positioning. The GLP-1 receptor agonist market—dominated by Novo Nordisk ($NVO), Eli Lilly ($LLY), and Roche ($RHHBY)—has expanded well beyond diabetes into obesity treatment, creating multibillion-dollar revenue streams. Aligos' exploration of synergistic combinations suggests potential to capture value in this rapidly expanding category.

Aligos' partnership strategy also merits attention. The Xiamen Amoytop Biotech collaboration for ALG-170675 development demonstrates an effective approach to de-risking R&D while accessing additional expertise and resources. Such partnerships have become increasingly common among mid-sized biotech companies seeking to maximize clinical productivity while managing cash burn.

Investor Implications: Runway Extension and Near-Term Catalysts

For investors, the improved financial position carries substantial implications. The transition from a $131.2 million annual burn rate in 2024 to $24.2 million in 2025 represents not merely cost-cutting, but evidence of disciplined execution and operational maturity. This efficiency gains may translate to extended clinical runway and reduced dilution risk if the company requires additional capital.

The Q3 2026 cash runway timeline creates a defined catalytic calendar:

• 2026 interim analyses from the B-SUPREME study could validate the pevifoscorvir sodium therapeutic hypothesis
• IND-enabling study progression for ALG-170675 may enable initiation of human trials by late 2026 or early 2027
• Continued metabolic disease data from ALG-055009 combination studies could substantiate partnership or out-licensing opportunities

The completion of HBeAg-negative enrollment in B-SUPREME deserves particular attention. This population represents the larger, more treatment-resistant segment of chronic hepatitis B patients, and successful demonstration of efficacy could support a broader patient population for later-stage development and commercialization.

However, investors should acknowledge inherent risks. Biotech companies operate within uncertain regulatory environments, clinical programs frequently encounter unexpected safety or efficacy challenges, and partnerships with smaller international entities like Xiamen Amoytop carry execution and operational risks. The cash runway into Q3 2026 also suggests potential need for capital raise or strategic alternatives if clinical programs advance without generating partnership revenue.

Looking Forward: A Company at an Inflection Point

Aligos Therapeutics presents a profile of a clinical-stage biopharmaceutical company successfully navigating the complex transition from capital-intensive research to disciplined clinical development. The 82% improvement in net loss, maintained cash position, and advancing pipeline suggest management has effectively allocated resources toward high-probability, high-impact programs.

The next 12-18 months will prove critical. Interim analyses from B-SUPREME, advancement of the ALG-170675 program, and expanded metabolic disease validation will determine whether Aligos can establish the clinical evidence base necessary to attract significant partnership interest or justify additional investment at favorable terms. For shareholders, these catalysts represent genuine inflection points in the company's value creation trajectory.

The improved financial discipline, combined with meaningful clinical progress in two distinct therapeutic areas, positions Aligos to execute a critical phase of clinical development without excessive dilution—a rare advantage for companies at this stage. Whether that execution translates to commercial success remains the fundamental question facing investors in the coming 12-24 months.